With expertise in research, fundraising, policy and more, our staff are dedicated to making breakthroughs possible. Hilary Evans-Newton is the Chief Executive of Alzheimer’s Research UK. Hilary joined ...

Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...

There are two main types of Alzheimer’s. Late onset Alzheimer’s starts after age 65, and young onset Alzheimer’s affects people before age 65. Different genes can be involved in the development of the ...

Dementia with Lewy bodies is the third most common disease that causes dementia. Both risk genes and faulty genes can be involved in dementia with Lewy bodies. Dementia with Lewy bodies (DLB) is ...

Gavin Patterson joins Alzheimer's Research UK as chair. The former President and Chief Revenue Officer of Salesforce and CEO ...

Research has found that people who led an active lifestyle, especially before 50 years old, had better brain health aged 70.

Alzheimer’s Research UK has a large number of different grant schemes through which you can apply for funding. All applications must fall within Alzheimer’s Research UK’s remit which covers biomedical ...

Welcome to the Thames Valley Network Centre. The Network Centre unites dementia researchers across the Universities of Oxford, Reading and Oxford Brookes. Here you can find out more about Network ...

Dementia Community Champions increase knowledge and understanding of dementia, brain health and dementia risk factors. They also emphasise the importance of taking part in research in their local ...

For the majority of people, genes are only one of many factors that may increase their risk of getting dementia. Other factors that affect our dementia risk include our age, lifestyle and environment.

READ-OUT is a new study underway trialling different types of blood tests in different groups of people across the UK ...